Paraneoplastik Otoantikorlar
Özet
Paraneoplastik sendromlar, kanserin doğrudan invazyonu veya metastazı dışında, malign ve normal dokular arasındaki immün çapraz reaksiyonlar veya humoral faktörler nedeniyle uzaktan ortaya çıkan sistemik bozukluklardır. En sık nörolojik sistemleri etkileyen bu sendromlar (PNS), vakaların %80'inde kanser tanısı konmadan önce saptanmaktadır. Bu durum, gizli tümörlerin erken evrede teşhis edilmesine olanak tanır. 2021 yılında PNS-Care paneli, PNS bağlamında antikorları kanser birlikteliği sıklığına göre üç gruba ayırmıştır: Kanser ilişkisi %70'ten fazla olan "Yüksek Riskli Antikorlar" (Hu, Yo, Ri, CV2/CRMP5, SOX1, PCA2, Amfifizin, Ma2/Ma, Tr, KLHL11); hücre içi antijenleri hedefler ve sitotoksik T hücre aracılı patogeneze sahiptir. Kanser ilişkisi %30-70 arasında olan "Orta Riskli Antikorlar" (AMPAR, GABABR, mGluR5, NMDAR, CASPR2, P/Q VGCC) ise hücre yüzeyi veya sinaptik proteinleri hedefleyerek doğrudan antikor aracılı mekanizmalarla çalışır. Üçüncü grup ise %30'dan az kanser ilişkisi gösteren düşük riskli gruptur. Tanı aşamasında serum ve BOS testlerinin birlikte yapılması önerilir. Pozitif yüksek riskli antikor saptandığında, ilk tarama negatif olsa bile tümör taramalarının 2 yıl boyunca 4-6 ayda bir tekrarlanması kritik önem taşır.
Paraneoplastic syndromes are systemic disorders caused by humoral factors or immune cross-reactivity between malignant and normal tissues, occurring remote from the primary tumor or metastasis. Most frequently inducing neurological manifestations, paraneoplastic neurological syndromes (PNS) are detected before a cancer diagnosis in 80% of cases, enabling the early identification of occult malignancies. In 2021, the PNS-Care panel updated the diagnostic criteria and classified onconeuronal antibodies into three risk categories based on their cancer association frequency. "High-Risk Antibodies" (>70% cancer-associated), such as Hu, Yo, Ri, and CV2/CRMP5, typically target intracellular antigens and are mediated by cytotoxic T-cell mechanisms. Conversely, "Intermediate-Risk Antibodies" (30%-70% cancer-associated), including NMDAR, AMPAR, GABABR, and P/Q VGCC, target cell surface or synaptic proteins, driving directly pathogenic antibody-mediated responses. "Low-Risk Antibodies" exhibit less than a 30% correlation with underlying malignancies. For robust diagnosis, concurrent testing of both serum and cerebrospinal fluid (CSF) is highly recommended. Clinically, identifying high-risk antibodies necessitates rigorous tumor screening every 4 to 6 months for a duration of 2 years, even if initial oncological screenings yield negative results.
Referanslar
Devine MF, Kothapalli N, Elkhooly M, Dubey D. Paraneoplastic neurological syndromes: clinical presentations and management. Ther Adv Neurol Disord 2020; 14: 1–19.
Vogrig A, Gigli GL, Segatti S, et al. Epidemiology of paraneoplastic neurological syndromes: a population-based study. J Neurol 2020; 267: 26–35.
Hébert J, Riche B, Vogrig A, et al. Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in France. Neurol Neuroimmunol Neuroinflamm 2020;7.
Graus F, Vogrig A, Muñiz-Castrillo S, et all. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm 2021; 8: e1014.
Grativvol RS, Cavalcante WCP, LHM Castro, Nitrini R, Simabukuro MM. Updates in the diagnosis and treatment of paraneoplastic neurologic syndromes. Neuro-oncology (S Nagpal, Section Editor). Current Oncology Reports 2018; 20:92 .
Sabater L, Gaig C, Gelpi E, Bataller L, Lewerenz J, Torres-Vega E, et al. A novel non-rapid-eye movement and rapid-eye-movement parasomniawith sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and postmortem study. Lancet Neurol 2014;13(6): 575–86.
Galli J, Greenlee J. Paraneoplastic Diseases of the Central Nervous System. F1000Res. 2020; 9: F1000 Faculty Rev-167.
Zekeridou A and Lennon VA. Neurologic autoimmunity in the era of checkpoint inhibitör cancer immunotherapy. Mayo Clin Proc 2019; 94: 1865–1878.
Binks SNM, Klein CJ, Waters P, et al. LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes. J Neurol Neurosurg Psychiatry 2018; 89: 526–534.
Kannoth S. Paraneoplastic neurologic syndrome: A practical approach. Ann Indian Acad Neurol 2012;15:6-12.
Gresa-Arribas N, Titulaer MJ, Torrents A, Aguilar E, McCracken L, Leypoldt F, et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol 2014; 13(2): 1672177
Hoftberger R, Titulaer MJ, Sabater L, et al. Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology,2013;81(17):1500-1506.
Hoftberger R, van Sonderen A, Leypoldt F, et al. Encephalitis and AMPA receptor antibodies: novel findings in a case series of 22 patients. Neurology 2015; 84(24): 2403-2412.
Honnorat J, Didelot A, Karantoni E, et al. Autoimmune limbic encephalopathy and anti-Hu antibodies in children without cancer. Neurology 2013; 80(24): 2226-2232.
Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016; 15(4): 391–404. A position letter based on literature review and gathered the experience of a team of experts with the aims of developing a practical, syndrome-based diagnostic approach to autoimmune encephalitis and providing guidelines to navigate through the differential diagnosis.
Perrone-Bizzozero N, Bird CW. Role of HuD in nervous system function and pathology. In: Schol (Ed.), Front Biosci 2013; 5: 554-563.
Lipka AF, Verschuuren JJ and Titulaer MJ. SOX1 antibodies in Lambert-Eaton myasthenic syndrome and screening for small cell lung carcinoma. Ann N Y Acad Sci 2012; 1275: 70–77.
Gadoth A, Kryzer T, Fryer J, McKeon A, Lennon V, Pittock S. Microtubule associated protein (MAP) 1B: novel paraneoplastic biomarker running head: MAP 1B-IgG: novel paraneoplastic biomarker. Ann Neurol 2017; 11: 81.
Jarius S, Wildemann B. ‘Medusa head ataxia’: the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. J Neuroinflammation. 2015; 12: 168.
Jitprapaikulsan J, Klein CJ, Pittock SJ, et al. Phenotypic presentations of paraneoplastic neuropathies associated with MAP1B-IgG. J Neurol Neurosurg Psychiatry 2019; 322175.
Irani SR. ‘Moonlighting’ surface antigens: a paradigm for autoantibody pathogenicity in neurology? Brain 2016; 139: 304–306.
Dubey D, Jitprapaikulsan J, Bi H, et al. Amphiphysin-IgG autoimmune neuropathy: a recognizable clinicopathologic syndrome. Neurology 2019; 93: e1873–e1880.
Armangu´e T, Sabater L, Torres-Vega E, et al. Clinical and immunological features of opsoclonus-myoclonus syndrome in the era of neuronal cell surface antibodies. JAMA Neurol 2016; 73(4): 417.
Armangue T, Titulaer MJ, Sabater L, et al. A novel treatment-responsive encephalitis with frequent opsoclonus and teratoma. Ann Neurol 2014; 75(3): 435-441.
Simard C, Vogrig A, Joubert B, et al. Clinical spectrum and diagnostic pitfalls of neurologic syndromes with Ri antibodies. Neurol Neuroimmunol Neuroinflamm 2020; 7: e699.
Krakenes T, Herdlevaer I, Raspotnig M, et al. CDR2L is the major Yo antibody target in paraneoplastic cerebellar degeneration. Ann Neurol 2019; 86: 316–321.
Venkatraman A and Opal P. Paraneoplastic cerebellar degeneration with anti-Yo antibodies – a review. Ann Clin Transl Neurol 2016; 3: 655–663.
Linnoila J, Guo Y, Gadoth A, et al. Purkinje cell cytoplasmic antibody type I (anti-Yo): predictive of gastrointestinal adenocarcinomas in men. J Neurol Neurosurg Psychiatry 2018; 89: 1116–1117.
Rosenfeld MR and Dalmau JO. Paraneoplastic disorders of the CNS and autoimmune synaptic encephalitis. Continuum 2012; 18: 366–383.
Adams C, McKeon A, Silber MH, et al. Narcolepsy, REM sleep behavior disorder, and supranuclear gaze palsy associated with Ma1 and Ma2 antibodies and tonsillar carcinoma. ArchNeurol 2011; 68: 521–524.
Ortega Suero G, Sola-Valls N, Escudero D, et al. Anti-Ma and anti-Ma2-associated paraneoplastic neurological syndromes. Neurologia 2018; 33: 18–27.
de Graaff E, et al. Identification of delta/notchlike epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration. Ann Neurol 2012; 71(6): 815-824.
Greene M, Lai Y, Baella N, Dalmau J, Lancaster E. Antibodies to delta/notch-like epidermal growth factor-related receptor in patients with anti-Tr, paraneoplastic cerebellar degeneration, and Hodgkin lymphoma. JAMA Neurol 2014; 71: 1003–1008.
Horta E, McKeon A, Lennon VA, Benarroch EE. Reversible paraneoplastic tonic pupil with PCATr-IgG and Hodgkin lymphoma. Neurology 2012; 78: 1620–1622.
Iorio R, Spagni G, Masi G. Paraneoplastic neurological syndromes. Seminars in Diagnostic Pathology 2019; 36(4): 4279-292.
Mandel-Brehm C, Dubey D, Kryzer TJ, et al. Kelch-like protein 11 antibodies in seminomaassociated paraneoplastic encephalitis. N Engl J Med 2019; 381: 47–54.
Dubey D, Wilson MR, Clarkson B, et al. Expanded clinical phenotype, oncological associations, and immunopathologic insights of paraneoplastic kelch-like protein-11 encephalitis. JAMA Neurol 2020; 77: 1–10.
Dubey D, Pittock SJ, Kelly CR, et al. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol 2018; 83: 166–177.
Zoya Zaeem, Collin C. Luk, Dustin Anderson, Gregg Blevins and Zaeem A. Siddiqi. AMPA-R Limbic Encephalitis Associated with Systemic Lupus Erythematosus. Canadian Journal of Neurological Sciences 2020; 47 (5): 709 – 710.
Byun JI, Lee ST, Jung KH et al (2016) Prevalence of antineuronal antibodies in patients with encephalopathy of unknown etiology: data from a nationwide registry in Korea. J Neuroimmunol 2016; 293: 34–38.
Zekeridou A, McKeon A and Lennon VA. Frequency of synaptic autoantibody accompaniments and neurological manifestations of thymoma. JAMA Neurol 2016; 73: 853–859.
Benarroch EE. GABAB receptors: structure, functions, and clinical implications. Neurology 2012;78:578–584.
Jeffery OJ, Lennon VA, Pittock SJ, et al. GABAB receptor autoantibody frequency in service serologic evaluation. Neurology 2013; 81: 882–887.
van Coevorden-Hameete MH, de Bruijn M, de Graaff E, et al. The expanded clinical spectrum of anti-GABABR encephalitis and added value of KCTD16 autoantibodies. Brain 2019; 142: 1631–1643.
Nicoletti F, et al. Metabotropic glutamate receptors: from the workbench to the bedside. Neuropharmacology 2011; 60: 1017–1041.
Lancaster E, Martinez-Hernandez E, Titulaer MJ, et al. Antibodies to metabotropic glutamatereceptor 5 in the Ophelia syndrome. Neurology 2011; 77: 1698–1701.
Spatola M, Sabater L, Planagumà J, et al. Encephalitis with mGluR5 antibodies:symptoms and antibody effects. Neurology 2018; 90: e1964–e1972.
Bien CG, et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain 2012; 135: 1622–1638
Irani SR and Vincent A. NMDA receptor antibody encephalitis. Curr Neurol Neurosci Rep 2011; 11: 298–304.
Gadoth A, Pittock SJ, Dubey D, et al. Expanded phenotypes and outcomes among 256 LGI 1/CASPR 2-I g G–positive patients. Ann Neurol 2017; 82: 79–92.
136-Boyko M, Au KLK, Casault C, et al. Systematic review of the clinical spectrum of CASPR2 antibody syndrome. J Neurol 2020; 267: 1137–1146.
van Sonderen A, Arino H, Petit-Pedrol M, et al. The clinical spectrum of Caspr2 antibodyassociated disease. Neurology 2016; 87: 521–528.
Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011; 10(12): 1098-1107.
